Oncology and Autoimmune Diseases
Indication——Advanced malignant solid tumors
(1) Can block the binding of PD-1 to PD-L1 to recover the function of T cells so that the immune system can kill tumor cells;
(2) Can block the binding between VEGF and VEGFR to degenerate the tumor vessels and normalize the surviving blood vessels to continuously inhibit angiogenesis, thereby achieving the control and treatment of tumors;
(3) Can target the tumor site to eliminate vascular epidermal growth factors in the tumor, thereby inhibiting the growth of new vessels at the tumor site effectively; better efficacy is expected in combination with anti-VEGF monoclonal antibodies (Avastin);
(4) A product yield of more than 6 g/L, which significantly improves the production capacity and reduces the production cost, thereby gaining competitiveness.
Next important events and time points
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the second quarter of 2021, and an IND application will be filed in the second quarter of 2022.